

Product Name: MK-0752 Revision Date: 01/10/2021

Product Data Sheet

MK-0752

Cat. No.: A4006

CAS No.: 471905-41-6

Formula: C21H21CIF2O4S


M.Wt: 442.9

Synonyms: MK 0752, MK0752

Target: Proteases

Pathway: Gamma Secretase

Storage: Store at -20°C



Solvent & Solubility

 \geqslant 22.15 mg/mL in DMSO; insoluble in H2O; \geqslant 48.8 mg/mL in EtOH with ultrasonic

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.2578 mL	11.2892 mL	22.5785 mL
	5 mM	0.4516 mL	2.2578 mL	4.5157 mL
	10 mM	0.2258 mL	1.1289 mL	2.2578 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	γ -secretase inhibitor	
IC ₅₀ & Target	5 nM (γ-secretase)	
	Cell Viability Assay	
In Vitro	Cell Line:	SH-SY5Y cells
	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining
		a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or
		shake it in the ultrasonic bath for a while. Stock solution can be stored below
		-20°C for several months.
	Reacting conditions:	IC50: 5 nM.
	Reacting conditions:	

	Applications:	As a moderately potent γ-secretase inhibitor, MK-0752 inhibited the production		
		of Aβ40 in a dose-dependent manner with an IC50 of 5 nM in human SH-SY5Y		
		cells.		
	Animal experiment			
	Animal models:	Male CMP rhesus monkeys		
	Dosage form:	Oral administration, 60 mg/kg and 240mg/kg		
	Applications:	Oral administration of MK-0752 demonstrated a dose-related reduction of Aβ		
	2000	levels. After 48 h, the Aβ levels with 240mg/kg treatment only recovered to		
In Vivo		50% of baseline, while the 60mg/kg treatment group reached baseline at 30 h		
		without overshoot. Plasma Aβ levels rebounded above baseline after MK-0752		
		inhibition (60 mg/kg, h 33–48).		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
		slightly differ with the theoretical value. This is caused by an experimental		
		system error and it is normal.		
	Bloggi			
		PE		
Product	Citations			

Product Citations

1. Chen X, Gong L, et al. "Sequential combination therapy of ovarian cancerwith cisplatin and γ-secretase inhibitor MK-0752." Gynecol Oncol. 2016Mar;140(3):537-44.PMID:26704638

See more customer validations on www.apexbt.com.

References

[1] Cook J J, Wildsmith K R, Gilberto D B, et al. Acute y-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-β production to alternative APP fragments without amyloid-β rebound[J]. The Journal of Neuroscience, 2010, 30(19): 6743-6750.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APE BIO

APE BIO

APE BIO

APE BIO

APE BIO